Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Francis Burrows, Tao Wu, Linda Kessler, Shuangwei Li, Jingchuan Zhang, Patrick Zarrinkar, Liansheng Li, Tomasz Cierpicki, Jolanta Grembecka, Pingda Ren and Yi Liu
Title A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML
Journal Mol Cancer Ther
Vol
Issue
Date
URL http://mct.aacrjournals.org/content/17/1_Supplement/LB-A27
Abstract Text Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
KO-539 KO-539 3 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
KO-539 KO-539 is a small molecule inhibitor of MEN1 (menin)-KMT2A (MLL1) complex, which may lead to growth inhibition of KMT2A (MLL1)-positive tumor cells (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
DNMT3A wild-type FLT3 mut NPM1 mut acute myeloid leukemia predicted - sensitive KO-539 Preclinical - Pdx Actionable In a preclinical study, KO-539 treatment prevented disease progression in patient-derived xenograft (PDX) models of DNMT3A wild-type acute myeloid leukemia harboring mutations in NPM1 and FLT3 (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). detail...
DNMT3A mut FLT3 exon 14 ins NPM1 mut acute myeloid leukemia predicted - sensitive KO-539 Preclinical - Pdx Actionable In a preclinical study, KO-539 treatment resulted in clearance of leukemia cells in patient-derived xenograft (PDX) models of acute myeloid leukemia harboring mutations in NPM1, DNMT3, and FLT3 exon 14 (ITD) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). detail...
KMT2A rearrange acute myeloid leukemia predicted - sensitive KO-539 Preclinical - Cell line xenograft Actionable In a preclinical study, KO-539 inhibited growth of KMT2A (MLL1)-rearranged acute myeloid leukemia cells in culture, and prolonged survival in cell-line xenograft models (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). detail...